[Federal Register Volume 85, Number 67 (Tuesday, April 7, 2020)]
[Notices]
[Page 19491]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07262]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-0626]
Pulmonary-Allergy Drugs Advisory Committee; Postponed
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee
(PADAC) scheduled for April 21, 2020, is postponed. The Food and Drug
Administration (FDA), like other government agencies, is taking the
necessary steps to ensure the Agency is prepared to continue our vital
public health mission in the event that our day-to-day operations are
impacted by the COVID-19 public health emergency. Therefore, we are
canceling or postponing all non-essential meetings through the month of
April. We will reassess on an ongoing basis for future months.
Therefore, this meeting is being postponed. The meeting was announced
in the Federal Register on February 20, 2020.
FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, Fax: 301-847-8533, email: [email protected], or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), and follow the prompts to the desired center or
product area. Please call the Information Line for up-to-date
information on this meeting, which was announced in the Federal
Register of February 20, 2020 (85 FR 9780).
Dated: April 1, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-07262 Filed 4-6-20; 8:45 am]
BILLING CODE 4164-01-P